Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (1): 7-15    DOI: 10.31083/j.ejgo.2020.01.4826
Original Research Previous articles | Next articles
Prognostic factors for types I and II epithelial ovarian cancer in the elderly
X.Z. Cheng1, †, Z. Zhou2, †, M.Y. Yang3, †, Y.L. Cai4, †, F. Deng1, X.X. Chen1, 5, *()
1 Department of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China
2 Department of Gynecology, Maternal and Child Care Service Centre of Lianyungang, Lianyungang, China
3 Department of Gynecology and Obstetrics, Yancheng Tumor Hospital, Yancheng, China
4 Department of Gynecology and Obstetrics, Zhongda Hospital Southeast University, Nanjing, China
5 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Download:  PDF(4113KB)  ( 365 ) Full text   ( 14 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: No consensus exists on whether age is independently associated with poor prognosis in epithelial ovarian cancer (EOC). This study aimed to examine the prognostic factors of EOC in elderly patients. Materials and Methods: A total of 665 EOC patients from Jiangsu Institute of Cancer Research (JICR, People's Republic of China) were retrospectively analyzed between 1996 and 2015. For validation, 990 cases who consulted at MD Anderson Cancer Center (MDACC, USA) from 1990 to 2011 were recruited. The associations between survival durations and covariates were assessed by Cox proportional hazards model and log-rank test. Results: Histological type II (p = 0.01) and suboptimal surgery outcome (p = 0.00) were more common in the elderly (age ≥ 70 years) patients with EOC than in younger patients from JICR. The International Federation of Gynecology and Obstetrics (FIGO) stage, histological type, and optimal surgery were independently associated with overall survival (OS; p = 0.00, p = 0.03, and p = 0.00, respectively) and progression-free survival (PFS; p = 0.00, p = 0.02, and p = 0.00, respectively) in the EOC patients. Both OS and PFS were lower in the elderly patients with type I EOC than in the younger cases (136.5 months vs. 191.8 months at p = 0.00 and 35.5 months vs. 75.1 months at p = 0.01, respectively). The OS and PFS of the elderly patients were poorer than those of the younger cases with type II EOC (38.4 months vs. 42.3 months at p = 0.00 and 14.9 months vs. 16.8 months, p = 0.04, respectively). In type II ovarian cancer patients who achieved optimal debulking, the median OS and PFS durations of younger patients remained longer than those of elderly patients (50.2 months vs. 68.0 months, p = 0.00 and 14.9 months vs. 19.2 months, p = 0.01, respectively). Conclusions: Compared with young patients, elderly EOC more commonly presented with an aggressive histological type and poor performance status and was more frequently undertreated. Advanced age was independently associated with poor prognosis in EOC, even after the influence of histological type and surgical outcome was eliminated.
Key words:  Epithelial ovarian cancer      Prognostic factors      Advanced age     
Published:  15 February 2020     
Fund: 
81472441/National Natural Science Foundation of China
2013-wsn-62/Six Major Talent Summit
*Corresponding Author(s):  X.X. CHEN     E-mail:  cxxxxcyd@gmail.com
About author:  Contributed equally.

Cite this article: 

X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.01.4826     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I1/7

[1] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[2] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[3] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[4] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[5] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[6] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[7] V. Loizzi, V. Del Vecchio, E. Pisani, G. Ranieri, L. Resta, E. Cicinelli, G. Cormio. Prognostic factors in endometrial cancer Stages III and IV: a single academic institution experience of 49 patients[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1000-1005.
[8] L. Bodnar, P. Knapp, J. Sznurkowski, R. Mądry, A. Gąsowska-Bodnar, M. Sikorska, A. Timorek, A. Ptak-Chmielewska, R. Jach, Polish Ovarian Cancer Group. Early initiation of chemotherapy after primary surgery as an adverse prognostic factor in patients with ovarian cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 236-241.
[9] L. Baquedano, S. Castan, M.A. Ruiz-Conde, M.A. Martinez-Maestre, D. Judez, P.J. Coronado. Prognostic factors in high-grade endometrial cancer: does subtype matter?[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 254-261.
[10] V. Pažin, A. Dobrosavljevic, L. Nejkovic. Primary fallopian tube carcinoma – case report[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 163-165.
[11] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[12] Jing Zhao, Xue Dong, Qing-cui Liu, Qun Lu. Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 769-772.
[13] Ying Yao, Le Chen, Huiying Yu, Hongyun Xiang, Jing Yao, Jie Tang. Clinical effects of comprehensive treatments for FIGO Stage IIB adenocarcinoma/adenosquamous carcinoma of the cervix[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 579-584.
[14] Li-Yuan Guo, San-Yuan Zhang, Chen Chen, Hao-Xia Zeng, Feng-Yan Li, Qiu-Xiang Xu. Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 615-620.
[15] K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.
No Suggested Reading articles found!